TAKEDA PHARMACEUTICAL CO LTD files 20-F

Takeda Pharmaceutical Company Limited reported a net loss of JPY 152.1 billion for the fiscal year ended March 31, 2026, a decrease from a net profit of JPY 108.1 billion in the prior year, primarily due to a JPY 403.5 billion provision for legal proceedings related to the AMITIZA antitrust litigation. Revenue for the year was JPY 4,505.7 billion, a 1.7% decrease from the previous fiscal year.